Frontier Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Frontier Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-5,346	Closed	-$279K	–	385
2014 Q4	$279K	Buy	+5,346	New	+$239K	﹤0.01%	324

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Frontier Capital Management's JUNO Position: Q1 2015 in Review

Frontier Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2015, closing a stake of 5,346 shares — an estimated $279K sold.

Frontier Capital Management first reported a position in JUNO in Q4 2014 and held it in 1 quarter. The position peaked at $279K in Q4 2014. 120 funds tracked by Wall St. Rank hold JUNO as of Q1 2015.

Frontier Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
Frontier Capital Management sold 5,346 Juno Therapeutics, Inc. shares in Q1 2015, an estimated $279K.
Frontier Capital Management first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 1 quarter.
Frontier Capital Management's Juno Therapeutics, Inc. position peaked at $279K in Q4 2014.
120 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2015.

Based on Frontier Capital Management's 13F filing for Q1 2015, filed 4 May 2015.